APPL-001 / Celularity - LARVOL DELTA

Celularity Announces Phase 1 Data Showing That MLASC Therapy in Patients With Crohn’s Disease May Be a Therapeutic Option to Manage Inflammatory Bowel Diseases and Prevent Fistula Formation (BioSpace) - "Celularity Inc...announced results from an exploratory analysis of Phase 1 data evaluating alterations in gene and protein signatures associated with reduced inflammation and fistula formation resulting from therapy with mesenchymal-like adherent stromal cells (MLASCs) in adult patients with Crohn’s disease (CD). These data were presented at the 26th Annual Meeting of the American Society of Gene & Cell Therapy, which is being held May 16-20th in Los Angeles....In this study, two patient groups were evaluated: patients who responded to MLASC therapy (n=12) and patients who received placebo (n=12). For each of the 24 patients, mRNA gene expression data and proteomics data were provided at early pre-treatment, at pre-treatment baseline, at early post-treatment) and at later post-treatment."

P1 data • Crohn's disease • Immunology • Inflammatory Bowel Disease

Celularity and GX Acquisition Corp. Announce Merger Agreement to Create a Publicly Listed Leader in Allogeneic Cellular Therapy (PRNewswire) - "Celularity Inc...announced they have entered into a definitive merger agreement pursuant to which GX Acquisition Corp...Upon the closing of the transaction, which is expected to occur in the second quarter of 2021, GX Acquisition Corp...APPL-001...for the treatment of degenerative diseases, including Crohn's disease. Celularity plans to submit an IND in the second half of 2021 and to commence a Phase 1/2a study of APPL-001 for the treatment of Crohn's disease in 2022."

IND • M&A • New P1/2 trial • Crohn's disease • Inflammatory Bowel Disease